Trial Profile
BIO-CHIC-Study BIOmarker driven and dose intensified CHemoImmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Etoposide phosphate (Primary) ; Methotrexate (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Therapeutic Use
- Acronyms BIO-CHIC
- 05 Dec 2019 Planned End Date changed from 13 Sep 2024 to 13 Sep 2025.
- 17 Oct 2016 New trial record